Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2020

01-12-2020 | Stroke | Research article

A prospective cohort study of MTHFR C677T gene polymorphism and its influence on the therapeutic effect of homocysteine in stroke patients with hyperhomocysteinemia

Authors: Xiaoxia Du, Lin Xiao, Rong Sun, Kunpeng Li, Lin Liang, Luping Song, Zhizhong Liu

Published in: BMC Neurology | Issue 1/2020

Login to get access

Abstract

Background

Hyperhomocysteinemia (HHCY) is a risk factor for cardiovascular and cerebrovascular diseases. The C677T 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism increases homocysteine (HCY) levels. This study analyzed the relationship between C677T MTHFR polymorphism and the therapeutic effect of lowering HCY in stroke patients with HHCY.

Methods

Baseline data were collected from stroke patients with HHCY for this prospective cohort study. The C677T MTHFR genotype was detected by polymerase chain reaction-restriction fragment length polymorphism and the therapeutic effect to reduce HCY was compared.

Results

Of 200 stroke patients 162 (81.0%) completed follow-up and were evaluated. Most of them responded well to treatment (103 cases, 63.5%), but 59 (36.4%) patients were in the poor efficacy group. There was a significant difference in terms of age (P < 0.001), hypertension (P = 0.041), hyperuricemia (P = 0.042), HCY after treatment (P < 0.001), and MTHFR genotype (P < 0.001) between the poor efficacy and effective groups, with increased frequency of the TT genotype in the poor efficacy group. Logistic regression showed that the T allele was associated with poor efficacy (OR = 0.733, 95%CI: 0.693, 0.862, P < 0.001). In the codominant model the TT genotype was associated with poor outcome (OR = 0.862, 95%CI: 0.767, 0.970, P = 0.017) and this was also the case in the recessive model (OR = 0.585, 95%CI: 0.462, 0.741, P < 0.001) but there was no association between CT and TT in the dominant model.

Conclusions

The T allele and TT genotype of the MTHFR C677T polymorphism was associated with poor HCY reduction treatment efficacy in stroke patients with HHCY.

Trial registration

The registration number of the clinical trial is ChiCTR1800020048​. Registration date: December 12, 2018.
Literature
1.
Bejot Y, Daubail B, Giroud M. Epidemiology of stroke and transient ischemic attacks: current knowledge and perspectives. Rev Neurol. 2016;172(1):59–68.PubMedCrossRef
2.
Uluduz D, Ince B, Bozluolcay M. Stroke patterns, etiology, and prognosis in patients with diabetes mellitus. Neurology. 2005;64(3):581 author reply 581.PubMedCrossRef
3.
Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry. 2003;74(3):312–6.PubMedPubMedCentralCrossRef
4.
Spence JD. Homocysteine lowering for stroke prevention: Unravelling the complexity of the evidence. Int J Stroke. 2016;11(7):744–7.PubMedCrossRef
5.
Li J, Jiang S, Zhang Y, Tang G, Wang Y, Mao G, Li Z, Xu X, Wang B, Huo Y. H-type hypertension and risk of stroke in chinese adults: a prospective, nested case-control study. J Transl Int Med. 2015;3(4):171–8.PubMedPubMedCentralCrossRef
6.
Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wilson PW, Wolf PA. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med. 1999;131(5):352–5.PubMedCrossRef
7.
Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr. 2006;136(6 Suppl):1726S–30S.PubMedCrossRef
8.
L S, CJZ L, al DXe. Comparison of etiology and risk factors between young and middle-aged and elderly patients with stroke. Chin J Med Guide. 2016;18(1):5–6.
9.
Li CJ, Du XX, Yang K, Song LP, Li PK, Wang Q, Sun R, Lin XL, Lu HY, Zhang T. Effects of professional rehabilitation training on the recovery of neurological function in young stroke patients. Neural Regen Res. 2016;11(11):1766–72.PubMedPubMedCentralCrossRef
10.
Hankey GJ, Eikelboom JW. Homocysteine and stroke. Lancet. 2007;365(9455):194–6.CrossRef
11.
Omrani HQ, Shandiz EE, Qabai M, Chaman R, Fard HA, Qaffarpoor M. Hyperhomocysteinemia, folateo and B12 vitamin in Iranian patients with acute ischemic stroke. ARYA Atherosclerosis. 2011;7(3):97–101.PubMedPubMedCentral
12.
Parnetti L, Caso V, Santucci A, Corea F, Lanari A, Floridi A, Conte C, Bottiglieri T. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci. 2004;25(1):13–7.PubMedCrossRef
13.
Kalita J, Kumar G, Bansal V, Misra UK. Relationship of homocysteine with other risk factors and outcome of ischemic stroke. Clin Neurol Neurosurg. 2009;111(4):364–7.PubMedCrossRef
14.
Dhamija RK, Gaba P, Arora S, Kaintura A, Kumar M, Bhattacharjee J. Homocysteine and lipoprotein (a) correlation in ischemic stroke patients. J Neurol Sci. 2009;281(1–2):64–8.PubMedCrossRef
15.
Kawamoto R, Kohara K, Oka Y, Tomita H, Tabara Y, Miki T. An association of 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and ischemic stroke. J Stroke Cerebrovasc Dis. 2005;14(2):67–74.PubMedCrossRef
16.
Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B, Zhu Z, Zhao J, Ma A, Han Y, et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a multicenter case-control study in China. Stroke. 2003;34(9):2085–90.PubMedCrossRef
17.
Song Y, Li B, Wang C, Wang P, Gao X, Liu G. Association between 5,10-Methylenetetrahydrofolate Reductase C677T gene polymorphism and risk of ischemic stroke: a meta-analysis. J Stroke Cerebrovasc Dis. 2016;25(3):679–87.PubMedCrossRef
18.
Sato S, Uehara T, Hayakawa M, Nagatsuka K, Minematsu K, Toyoda K. Intra- and extracranial atherosclerotic disease in acute spontaneous intracerebral hemorrhage. J Neurol Sci. 2013;332(1–2):116–20.PubMedCrossRef
19.
Zhou Z, Liang Y, Qu H, Zhao M, Guo F, Zhao C, Teng W. Plasma homocysteine concentrations and risk of intracerebral hemorrhage: a systematic review and meta-analysis. Sci Rep. 2018;8(1):2568.PubMedPubMedCentralCrossRef
20.
21.
Brattstrom L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Investig. 1992;22(3):214–21.CrossRef
22.
Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH, Willett WC. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol. 1996;143(9):845–59.PubMedCrossRef
23.
Kalita J, Srivastava R, Bansal V, Agarwal S, Misra UK. Methylenetetrahydrofolate reductase gene polymorphism in Indian stroke patients. Neurol India. 2006;54(3):260–3.PubMedCrossRef
24.
Kumar A, Kumar P, Prasad M, Sagar R, Yadav AK, Pandit AK, Jali VP, Pathak A. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene (MTHFR gene) with ischemic stroke: a meta-analysis. Neurol Res. 2015;37(7):568–77.PubMedCrossRef
25.
Banerjee I, Gupta V, Ganesh S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: a meta-analysis. J Hum Genet. 2007;52(3):205–19.PubMedCrossRef
26.
Harbuzova V, Polonikov OV, Stroi DO, Matlai OI, Ataman Iu O, Sukharieva VA, Ataman OV. Analysis of the effect of N5, N10-methylenetetrahydrofolate reductase gene C(677)-->T polymorphism on the ischemic stroke development in persons with various risk factors. Fiziolohichnyi zhurnal. 2014;60(2):18–24.PubMedCrossRef
27.
Lv Q, Lu J, Wu W, Sun H, Zhang J. Association of the methylenetetrahydrofolate reductase gene A1298C polymorphism with stroke risk based on a meta-analysis. Genet Mol Res. 2013;12(4):6882–94.PubMedCrossRef
28.
Zhu XY, Hou RY, Pan XD, Wang YC, Zhang ZS, Guo RY. Association between the methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism and ischemic stroke in the Chinese population: a meta-analysis. Int J Neurosci. 2015;125(12):885–94.PubMedCrossRef
29.
Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke. 2005;36(7):1581–7.PubMedCrossRef
30.
Zhao M, Wang X, He M, Qin X, Tang G, Huo Y, Li J, Fu J, Huang X, Cheng X, et al. Homocysteine and stroke risk: modifying effect of Methylenetetrahydrofolate Reductase C677T polymorphism and folic acid intervention. Stroke. 2017;48(5):1183–90.PubMedCrossRef
31.
The 2010 Guidelines for the diagnosis and treatment of acute ischemic stroke in China. Chinese J Clinic. 2011;39(3):227–233.
32.
Wang X. Essentials for diagnosis of various cerebrovascular diseases. Chin J Neurol. 1997;3(1):3–4.
33.
Bhargava S, Parakh R, Srivastava LM. Studies on homocysteine demonstrating its significance as a possible tool for differential diagnosis in occlusive vascular disease. Ind J Clin Biochem. 2004;19(1):76–8.CrossRef
34.
Shen H, Xu Y, Zheng Y, Qian Y, Yu R, Qin Y, Wang X, Spitz MR, Wei Q. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. Int J Cancer. 2001;95(5):332–6.PubMedCrossRef
35.
Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet. 1998;62(5):1258–60.PubMedPubMedCentralCrossRef
36.
Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C-->T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost. 1998;79(1):119–21.PubMedCrossRef
37.
Baum L, Wong KS, Ng HK, Tomlinson B, Rainer TH, Chan DK, Thomas GN, Chen X, Poon P, Cheung WS, et al. Methylenetetrahydrofolate reductase gene A222V polymorphism and risk of ischemic stroke. Clin Chem Lab Med. 2004;42(12):1370–6.PubMedCrossRef
38.
Goracy I, Cyrylowski L, Kaczmarczyk M, Fabian A, Koziarska D, Goracy J, Ciechanowicz A. C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of ischemic stroke in polish subjects. J Appl Genet. 2009;50(1):63–7.PubMedCrossRef
39.
Moe KT, Woon FP, De Silva DA, Wong P, Koh TH, Kingwell B, Chin-Dusting J, Wong MC. Association of acute ischemic stroke with the MTHFR C677T polymorphism but not with NOS3 gene polymorphisms in a Singapore population. Eur J Neurol. 2008;15(12):1309–14.PubMedCrossRef
40.
Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57(1):47–53.PubMedCrossRef
41.
Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754–832.PubMedPubMedCentralCrossRef
42.
Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Heart outcomes prevention evaluation I: Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40(4):1365–72.PubMedCrossRef
43.
Ji Y, Tan S, Xu Y, Chandra A, Shi C, Song B, Qin J, Gao Y. Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: a meta-analysis. Neurology. 2013;81(15):1298–307.PubMedCrossRef
44.
Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340(19):1449–54.PubMedCrossRef
45.
Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517–84.PubMedCrossRef
46.
Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(2):577–617.PubMedCrossRef
47.
Kang SS, Wong PW, Bock HG, Horwitz A, Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet. 1991;48(3):546–51.PubMedPubMedCentral
48.
Cybulska B, Klosiewicz-Latoszek L. Homocysteine--is it still an important risk factor for cardiovascular disease? Kardiol Pol. 2015;73(11):1092–6.PubMedCrossRef
49.
Towfighi A, Markovic D, Ovbiagele B. Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: a nationwide study. J Neurol Sci. 2010;298(1–2):153–7.PubMedCrossRef
Metadata
Title
A prospective cohort study of MTHFR C677T gene polymorphism and its influence on the therapeutic effect of homocysteine in stroke patients with hyperhomocysteinemia
Authors
Xiaoxia Du
Lin Xiao
Rong Sun
Kunpeng Li
Lin Liang
Luping Song
Zhizhong Liu
Publication date
01-12-2020
Publisher
BioMed Central
Keywords
Stroke
Folic Acid
Published in
BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-020-01701-8

Other articles of this Issue 1/2020

BMC Neurology 1/2020 Go to the issue

Research article

T2 mapping of molecular subtypes of WHO grade II/III gliomas

Research article

Outcomes of thrombolytic therapy in acute ischemic stroke: mothership, drip-and-ship, and ship-and-drip paradigms

Case report

Injury of Corticospinal tract and Corticoreticular pathway caused by high-voltage electrical shock: a case report

Research article

Cost-effectiveness of the PDSAFE personalised physiotherapy intervention for fall prevention in Parkinson’s: an economic evaluation alongside a randomised controlled trial

Case report

Hereditary hemorrhagic telangiectasia associated with cortical development malformation due to a start loss mutation in ENG

Correction

Correction to: Transient ischemic attack presenting as recurrent migratory numbness by seconds: a rare case confirmed by transcranial Doppler micro-emboli monitoring